TY - JOUR
T1 - Governing Heritable Human Genome Editing
T2 - A Textual History and a Proposal for the Future
AU - Walters, Le Roy
AU - Cook-Deegan, Robert M.
AU - Adashi, Eli Y.
N1 - Funding Information: The ‘‘Points to Consider’’ became Appendix M to the NIH ‘‘Guidelines for Research Involving Recombinant DNA Molecules.’’ As such, they created requirements for investigators funded by the NIH. However, the ‘‘Points to Consider’’ were never formally promulgated as federal regulations. The ‘‘Points to Consider’’ did not preempt federal, state, or local law. They also did not prohibit the conduct of germline gene transfer research that was privately funded, but merely offered the option of voluntary RAC review. Funding Information: This work was supported by National Cancer Institute, 5R01CA237118: The Sulston Project: Making the Knowledge Commons for Interpreting Cancer Genomic Variants More Effective (Robert M. Cook-Deegan and Amy L. McGuire, Co-Principal Investigators). Publisher Copyright: © LeRoy Walters, et al. 2021; Published by Mary Ann Liebert, Inc. 2021.
PY - 2021/8
Y1 - 2021/8
N2 - Heritable human genome editing (HHGE) has become a topic of intense public interest, especially since 2015. In the early 1980s, a related topic-human genetic engineering-was the subject of sustained public discussion. There was particular concern about germline genetic intervention. During the 1980s debate, an advisory committee to the Director of the National Institutes of Health (NIH)-the Recombinant DNA Advisory Committee (RAC)-agreed to provide initial public review of proposals for deliberate introduction of DNA into human beings. In 1984 and 1985, the RAC developed guidelines for research involving DNA transfer into patients. The committee also commented on the possibility of deliberately altering the human germline. We track the textual changes over time in the RAC's response to the possibility of germline genetic intervention in humans. In 2019, the NIH RAC was abolished. New techniques for genome editing, including CRISPR-based techniques, make both somatic and germline alterations much more feasible. These novel capabilities have again raised questions about oversight. We propose the creation of a new structure for the public oversight of proposals to perform HHGE. In parallel with a technical review by a regulatory agency, such proposals should also be publicly evaluated by a presidentially appointed Bioethics Advisory Commission.
AB - Heritable human genome editing (HHGE) has become a topic of intense public interest, especially since 2015. In the early 1980s, a related topic-human genetic engineering-was the subject of sustained public discussion. There was particular concern about germline genetic intervention. During the 1980s debate, an advisory committee to the Director of the National Institutes of Health (NIH)-the Recombinant DNA Advisory Committee (RAC)-agreed to provide initial public review of proposals for deliberate introduction of DNA into human beings. In 1984 and 1985, the RAC developed guidelines for research involving DNA transfer into patients. The committee also commented on the possibility of deliberately altering the human germline. We track the textual changes over time in the RAC's response to the possibility of germline genetic intervention in humans. In 2019, the NIH RAC was abolished. New techniques for genome editing, including CRISPR-based techniques, make both somatic and germline alterations much more feasible. These novel capabilities have again raised questions about oversight. We propose the creation of a new structure for the public oversight of proposals to perform HHGE. In parallel with a technical review by a regulatory agency, such proposals should also be publicly evaluated by a presidentially appointed Bioethics Advisory Commission.
UR - http://www.scopus.com/inward/record.url?scp=85113311575&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113311575&partnerID=8YFLogxK
U2 - 10.1089/crispr.2021.0043
DO - 10.1089/crispr.2021.0043
M3 - Review article
C2 - 34406046
SN - 2573-1599
VL - 4
SP - 469
EP - 476
JO - CRISPR Journal
JF - CRISPR Journal
IS - 4
ER -